Internal Medicine, Endocrinology, Diabetes, & Metabolism · Fort Collins, CO
NPI
1093723231
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2121 E Harmony Rd, Suite 230
Fort Collins, CO, 80528
Phone (970) 295-0010
Groups this clinician bills Medicare through
Medicare paid, 2024
$146K
6,948 services
Medicare patients, 2024
382
Average age 72
Drug cost, 2024
$1.7M
4,743 prescriptions
Company payments, 2025
$144
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Meriam P Izon was code J0897 (injection, denosumab, 1 mg), 1,020 times for 12 patients. In total Meriam P Izon billed 6,948 services in 16 codes, and Medicare paid $146K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-01-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,020 | 12 | $20.28 | $21K |
| 99214 Office E&M - Established | Office | 658 | 340 | $90.81 | $60K |
| 95251 Test - Miscellaneous | Office | 290 | 101 | $26.09 | $7,565 |
| 95250 Test - Miscellaneous | Office | 82 | 34 | $114.84 | $9,417 |
| 96372 Injection Administration | Office | 59 | 20 | $10.26 | $605 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 58 | 55 | $7.17 | $416 |
| 99204 Office E&M - New | Office | 53 | 53 | $113.47 | $6,014 |
| 99211 Office E&M - Established | Office | 51 | 33 | $17.60 | $898 |
| 83036 Blood Count | Office | 20 | 16 | $9.52 | $190 |
By year: 2022 $137K for 5,023 services; 2023 $213K for 15,804 services; 2024 $146K for 6,948 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 20 | 16 | $9.52 | $190 |
Medicare prescription drug claims, 2024
In 2024, the drug Meriam P Izon prescribed most often to Medicare patients was Levothyroxine Sodium, with 640 prescriptions and refills. In total Meriam P Izon wrote 4,743 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 640 | 1,753 | 169 | $5,833 |
| Metformin Hcl Er Metformin Hcl | 258 | 747 | 71 | $3,548 |
| Synthroid Levothyroxine Sodium | 246 | 670 | 53 | $20K |
| Rosuvastatin Calcium Generic | 244 | 708 | 71 | $2,983 |
| Jardiance Empagliflozin | 212 | 474 | 55 | $274K |
| Atorvastatin Calcium Generic | 197 | 548 | 54 | $1,707 |
| Lisinopril Generic | 178 | 502 | 53 | $1,318 |
| Ozempic Semaglutide | 141 | 285 | 32 | $275K |
| Mounjaro Tirzepatide | 128 | 159 | 19 | $169K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 113 | 261 | 43 | $16K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 107 | 286 | 40 | $18K |
| Glimepiride Generic | 101 | 298 | 29 | $1,078 |
| Losartan Potassium Generic | 94 | 275 | 31 | $852 |
| Humalog Kwikpen U-100 Insulin Lispro | 85 | 212 | 35 | $38K |
| Novolog Flexpen Insulin Aspart | 82 | 160 | 23 | $27K |
Brand drugs: 2,041 claims; generic drugs: 2,377 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Meriam P Izon $144 ($144 in general payments such as food, travel and fees) from 1 company. The largest payer was Beta Bionics, Inc. with $144.
| Company | Payments | Amount |
|---|---|---|
| Beta Bionics, Inc. BBNX | 1 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.